Navigation Links
NxStage Medical Provides Update on Medisystems Acquisition
Date:8/29/2007

kets innovative systems for the treatment of end-stage renal disease, or ESRD, and acute kidney failure. For more information on NxStage and its products, please visit the Company's website at http://www.nxstage.com.

Forward-Looking Statements

This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Examples of these forward-looking statements include statements as to the anticipated closing of the Medisystems transaction, the anticipated performance of certain executives, and expected benefits of the Medisystems transaction. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond NxStage's control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance or achievements, including factors that may affect future operating results and which are detailed in NxStage's filings with the Securities and Exchange Commission, including the Annual Report on Form 10-K for the year ended December 31, 2006 and the Quarterly Report on Form 10-Q for the quarter ended June 30, 2007.

In addition, the statements in this press release represent NxStage's expectations and beliefs as of the date of this press release. NxStage anticipates that subsequent events and developments may cause these expectations and beliefs to change. However, while NxStage may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, whether as a result of new information, future events, or otherwise. These forward-looking statements shoul
'/>"/>

SOURCE NxStage Medical, Inc.
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Medical College receives $377K to study brain disease
2. Barriers will not stop convergence of medical technologies
3. Medical College team creates website for tracking flu
4. Biomedical engineering conference invites manufacturers
5. Visions: Wade offers straight talk on e-medical records
6. Merge unveils updated medical imaging software
7. Medical College receives $1.4M cancer grant
8. Medical technology firm lands $100K federal grant
9. Doyle outlines spending for Medical College, UWM
10. And the winners in medical design are
11. Manufacturing partnership will move into biotech and biomedical spaces
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)... NEW YORK, Dec. 2 Nearly 600 medical research ... explore novel development approaches and innovative funding strategies at ... ,, FasterCures, the Washington-based center of the ... facilitate multi-sector collaborations needed to turn a scientific discovery ...
(Date:12/2/2009)... , - "Bolstering ... Coinciding with the International ... is hosting an international conference in Libreville,(Gabon) on ... The,conference will be attended by government and state ...
(Date:12/2/2009)... announced data presentations on its novel oral JAK2 inhibitor, ... Meeting and Exposition in New Orleans. ,, Data will ... 1 dose-escalation trial of SB1518 detailing its safety, tolerability ... 100 to 600 mg. These doses were administered once ...
(Date:12/2/2009)... SHANGHAI, Dec. 2 /PRNewswire-Asia/ -- The world is going ... part of many,businesses and industries. It turns out that ... downturn, because illness doesn,t take a,vacation. , ... this year, the pharmaceutical,giant Johnson & Johnson inaugurated an ...
Breaking Biology Technology:Medical Research Leaders Explore Novel Strategies to Expedite the Search for Cures 2Libreville International Conference 2-3 June 2010 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 2Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 3
... Inc.,(Nasdaq: SUPG ), a pharmaceutical company dedicated ... for solid tumors and,hematological malignancies, today announced that ... is scheduled to present at the Thomas,Weisel Partners ... Four,Seasons Hotel in Boston. SuperGen,s presentation at ...
... ADVENTRX Pharmaceuticals,Inc. (Amex: ANX ) a biopharmaceutical ... candidates for the treatment,of cancer and infectious diseases, ... officer, is scheduled to present at the 2007,Thomas ... at 1:30 p.m. Eastern Daylight Time. The conference ...
... 28 DOV Pharmaceutical,Inc. ("DOV" or the "Company") (OTC ... common stock is now being quoted on the OTC,Bulletin ... also still,being quoted on the Pink Sheets. "We ... now being quoted,both on the OTC Bulletin Board and ...
Other Biology Technology:ADVENTRX Pharmaceuticals to Present at the 2007 Thomas Weisel Partners Healthcare Conference 2DOV Pharmaceutical, Inc. Begins Trading on OTC Bulletin Board 2
(Date:12/4/2009)... CORVALLIS, Ore. According to an analysis of statewide ... less than $50,000 a year were more than three ... health providers because of their insurance status during pregnancy ... discrimination was also three times more likely among mothers ...
(Date:12/4/2009)... Royal Botanic Gardens, Kew and the Natural History Museum ... widespread than previously thought, with many commonly grown plants ... to being "meat eaters". A review paper, Murderous plants: ... is published today (4 December 2009) in the ...
(Date:12/4/2009)... is available in German . , A ... Ageing could help to understand the positive effect of dietary ... flies and mice) have shown that dietary restriction increases longevity, ... So the female fruit fly reproduces less frequently with a ...
Breaking Biology News(10 mins):Lower income women report more insurance-based discrimination during pregnancy, delivery 2Scientists think 'killer petunias' should join the ranks of carnivorous plants 2How nutrition affects healthy aging 2Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 1Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 2Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 3Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 4Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 5Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 6Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 7Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 8Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 9Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 10Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 11Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 12Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 13Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 14Webcast Alert 3A Usinas Siderurgicas de Minas Gerais S A USIMINAS Announces Third Quarter 2009 Results Webcast 59442 1Webcast Alert 3A Usinas Siderurgicas de Minas Gerais S A USIMINAS Announces Third Quarter 2009 Results Webcast 59442 2Cardium Announces Commercial Development of Excellagen 28TM 29 a Customized Collagen Based Topical Gel for Initial Use as an Adjunct to Surgical Debri 59439 1Cardium Announces Commercial Development of Excellagen 28TM 29 a Customized Collagen Based Topical Gel for Initial Use as an Adjunct to Surgical Debri 59439 2Cardium Announces Commercial Development of Excellagen 28TM 29 a Customized Collagen Based Topical Gel for Initial Use as an Adjunct to Surgical Debri 59439 3Cardium Announces Commercial Development of Excellagen 28TM 29 a Customized Collagen Based Topical Gel for Initial Use as an Adjunct to Surgical Debri 59439 4Cardium Announces Commercial Development of Excellagen 28TM 29 a Customized Collagen Based Topical Gel for Initial Use as an Adjunct to Surgical Debri 59439 5Cardium Announces Commercial Development of Excellagen 28TM 29 a Customized Collagen Based Topical Gel for Initial Use as an Adjunct to Surgical Debri 59439 6Cardium Announces Commercial Development of Excellagen 28TM 29 a Customized Collagen Based Topical Gel for Initial Use as an Adjunct to Surgical Debri 59439 7Cardium Announces Commercial Development of Excellagen 28TM 29 a Customized Collagen Based Topical Gel for Initial Use as an Adjunct to Surgical Debri 59439 8
... responsible for the single most common cause of hearing ... the first time, a scientist told the annual conference ... France. Ms Melissa Thys, from the Department of Medical ... may be a step towards new treatments for otosclerosis, ...
... nanoparticle made in a laboratory at the University of ... device for treating glaucoma, an eye disease that can ... “The nanoparticle can safely get past the blood-brain barrier ... said Sudipta Seal, an engineering professor with appointments in ...
... announced this week the discovery of a mechanism by ... in serious lung infections and is prevalent in emphysema ... or “macrophages” and thus compromises the body’s immunity. , ... State University, will be published online this week in ...
Other Biology News:Gene responsible for common hearing loss identified for first time 2UCF nanoparticle offers promise for treating glaucoma 2Researchers discover 'acquired' DNA key to certain bacterial infection 2
F40 piston seals are supplied as 2 seals with a seal tool to service one F40 pump of a BioLogic DuoFlow workstation....
... This depletion cocktail is ... (CD3+CD4+CD8+) cells from suspensions of ... Cells are separated using the ... immunomagnetic negative selection system, achieving ...
...
... This depletion cocktail is tailored ... cells from suspensions of non-human ... are separated using the StemSep ... selection system. The CD4+ T ...
Biology Products: